Indication: For the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome
Pharmacology: Cevimeline is a cholinergic agonist which binds to muscarinic receptors. Cevimeline is indicated for the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome.
Mechanism Of Action: Muscarinic agonists such as cevimeline in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointestinal and urinary tracts.
Drug Category: Parasympathomimetics; Muscarinic Agonists
Absorption: Rapidly absorbed with peak concentration after 1.5 to 2 hours
Interactions:
DrugBank: Interactions for Cevimeline
Interactions for Cevimeline:
Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the
possibility of conduction disturbances. Drugs with parasympathomimetic effects administered concurrently with
cevimeline can be expected to have additive effects. Cevimeline might interfere with desirable antimuscarinic effects
of drugs used concomitantly.
Drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline. Cevimeline should be used with
caution in individuals known or suspected to be deficient in CYP2D6 activity, based on previous experience, as they
may be at a higher risk of adverse events. In an in vitro study, cytochrome P450 isozymes 1A2, 2A6, 2C9, 2C19,
2D6, 2E1, and 3A4 were not inhibited by exposure to cevimeline.
Chemical IUPAC Name: 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
